KRAS is a common type of oncogene and is involved in at least one-fifth of all human cancers. KRAS mutations cause 32% of lung tumors and 96% of pancreatic tumors. However, after more than 30 years of research, there is still no effective treatment strategy for this oncogene. For this reason, many studies have been conducted to try to identify other molecules that show therapeutic activity along the KRAS signaling…
Month: September 2020
New Regulation Mechanism of Interferon Signaling Pathway
The interferon (IFN) signaling pathway is the main component of innate immunity and plays an important role in the host’s resistance to pathogens; the production of IFN and the activation of downstream pathways are precisely regulated. The transcription factor STAT1 is a key effector of the IFN pathway. When the IFN signaling pathway is activated, the STAT1 protein is phosphorylated and modified by its kinase JAK1 to form heterologous or…